MRTX Analyst Price Targets - Benzinga

SPY769.86+0.03%QQQ749.55−0.00%BTC/USD85,250.64+0.60%DIA511.70+0.12%GLD380.52+0.10%TLT77.53+0.06%

MRTX

MRTXNasdaq Private Market

Private market price is not available

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

MRTX Analyst Price Targets - Benzinga

MRTX Analyst Price Targets

Wall Street analyst price targets and consensus rating for MRTX (MRTX).

Price Target Range — 1 Quarters

Analyst Consensus — 9 Analysts

9Hold

Consensus RatingNeutral# Analysts9Avg. Consensus PT$60

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 20, 2023	Citigroup	Yigal Nochomovitz	Downgrade	Buy→Neutral	$48→$59
Nov 7, 2023	Leerink Partners	Andrew Berens	Downgrade	Outperform→Market Perform	$78→$58
Nov 7, 2023	Stifel	Benjamin Burnett	Downgrade	Buy→Hold	$83→$59
Oct 10, 2023	Piper Sandler	Joseph Catanzaro	Downgrade	Overweight→Neutral	$58
Oct 9, 2023	B. Riley Securities	Kalpit Patel	Downgrade	Buy→Neutral	$65→$60
Oct 9, 2023	Scotiabank	George Farmer	Upgrade	Sector Underperform→Sector Perform	$58
Oct 9, 2023	Jefferies	Maury Raycroft	Downgrade	Buy→Hold	$55→$58
Oct 9, 2023	JMP Securities	Silvan Tuerkcan	Downgrade	Market Outperform→Market Perform	—
Oct 6, 2023	Stifel	Benjamin Burnett	Maintained	Buy	$83
Oct 6, 2023	BMO Capital	Evan David Seigerman	PT Raise	Market Perform	$31→$72
Oct 6, 2023	JMP Securities	Silvan Tuerkcan	PT Raise	Market Outperform	$58→$82

More with Benzinga EdgeGet Access

Analyst Ratings News

EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Avi Kapoor

Analyst Expectations For Mirati Therapeutics's Future

Benzinga Insights

PRO
Citigroup Downgrades Mirati Therapeutics to Neutral, Raises Price Target to $59

Citigroup analyst Yigal Nochomovitz downgrades Mirati Therapeutics (NASDAQ:MRTX) from Buy to Neutral and raises the price target from $48 to $59.

Benzinga Newsdesk

What 11 Analyst Ratings Have To Say About Mirati Therapeutics

Benzinga Insights

PRO
Leerink Partners Downgrades Mirati Therapeutics to Market Perform, Lowers Price Target to $58

Leerink Partners analyst Andrew Berens downgrades Mirati Therapeutics (NASDAQ:MRTX) from Outperform to Market Perform and lowers the price target from $78 to $58.

Benzinga Newsdesk

Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Lisa Levin